Crystal structure of human cytochrome P450 2D6 with prinomastat bound

Journal of Biological Chemistry

Volumn 287, Issue 14, 2012, Pages 10834-10843

  Wang, An ^a   Savas, Uzen ^a   Hsu, Mei Hui ^a   Stout, C David ^a   Johnson, Eric F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITE; CATALYTIC VERSATILITY; CLINICAL PRACTICES; ELECTRON DENSITY MAPS; HEME IRON; HUMAN CYTOCHROME; IN-SILICO; LIGAND COMPLEXES; LIGAND-FREE STRUCTURES; OPEN CAVITY; POTENT INHIBITOR; PROTEIN DATA BANK; PYRIDYL; STRUCTURAL FLEXIBILITIES; SUBSTRATE INTERACTION;

PORPHYRINS; X RAY CRYSTALLOGRAPHY;

COMPLEXATION;

CYTOCHROME P450 2D6; PRINOMASTAT;

ALLELE; ALPHA HELIX; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BETA SHEET; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG INTERACTION; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME SUBSTRATE COMPLEX; GENETIC VARIABILITY; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; HUMANS; LIGANDS; MODELS, MOLECULAR; ORGANIC CHEMICALS; PROTEIN BINDING;

EID: 84859500879     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.307918     Document Type: Article

References (37)

1. Zanger, U. M., Turpeinen, M., Klein, K., and Schwab, M. (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 392, 1093-1108
2. Wang, B., Yang, L. P., Zhang, X. Z., Huang, S. Q., Bartlam, M., and Zhou, S. F. (2009) New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab. Rev. 41, 573-643
3. Ingelman-Sundberg, M., and Sim, S. C. (2010) Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochem. Biophys. Res. Commun. 396, 90-94
4. Kroemer, H. K., and Eichelbaum, M. (1995) "It's the genes, stupid." Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci. 56, 2285-2298
5. Zhou, S. F., Liu, J. P., and Chowbay, B. (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev. 41, 89-295
6. Rowland, P., Blaney, F. E., Smyth, M. G., Jones, J. J., Leydon, V. R., Oxbrow, A. K., Lewis, C. J., Tennant, M. G., Modi, S., Eggleston, D. S., Chenery, R. J., and Bridges, A. M. (2006) Crystal structure of human cytochrome P450 2D6. J. Biol. Chem. 281, 7614-7622 (Pubitemid 43847532)
7. Wester, M. R., Johnson, E. F., Marques-Soares, C., Dansette, P. M., Mansuy, D., and Stout, C. D. (2003) Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 Å resolution. Evidence for multiple substrate binding modes. Biochemistry 42, 6370-6379
8. Mast, N., White, M. A., Bjorkhem, I., Johnson, E. F., Stout, C. D., and Pikuleva, I. A. (2008) Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1; the principal cholesterol hydroxylase in the brain. Proc. Natl. Acad. Sci. U.S.A. 105, 9546-9551 (Pubitemid 352031338)
9. Halpert, J. R. (2011) Structure and function of cytochromes P450 2B. From mechanism-based inactivators to x-ray crystal structures and back. Drug Metab. Dispos. 39, 1113-1121
10. Sansen, S., Yano, J. K., Reynald, R. L., Schoch, G. A., Griffin, K. J., Stout, C. D., and Johnson, E. F. (2007) Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J. Biol. Chem. 282, 14348-14355 (Pubitemid 47100434)
11. Wang, A., Savas, U., Stout, C. D., and Johnson, E. F. (2011) Structural characterization of the complex between α-naphthoflavone and human cytochrome P450 1B1. J. Biol. Chem. 286, 5736-5743
12. Gegner, J. A., and Dahlquist, F. W. (1991) Signal transduction in bacteria: Che W forms a reversible complex with the protein kinase CheA. Proc. Natl. Acad. Sci. U.S.A. 88, 750-754 (Pubitemid 21916101)
13. Barnes, H. J. (1996) Maximizing expression of eukaryotic cytochrome P450s in Esherichia coli. Methods Enzymol. 272, 3-14
14. Wester, M. R., Stout, C. D., and Johnson, E. F. (2002) Purification and crystallization of N-terminally truncated forms of microsomal cytochrome P450 2C5. Methods Enzymol. 357, 73-79 (Pubitemid 35231345)
15. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J. Biol. Chem. 239, 2379-2385
16. Dehal, S. S., and Kupfer, D. (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 57, 3402-3406 (Pubitemid 27355484)
17. Collaborative Computational Project, Number 4 (1994) The CCP4 suite. Programs for protein crystallography. Acta Crystallogr.DBiol. Crystallogr. 50, 760-763
18. McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C., and Read, R. J. (2005) Likelihood-enhanced fast translation functions. Acta Crystallogr. D Biol. Crystallogr. 61, 458-464 (Pubitemid 43934606)
19. Emsley, P., and Cowtan, K. (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (Pubitemid 41742764)
20. Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography & NMR system. A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905-921
21. Wester, M. R., Johnson, E. F., Marques-Soares, C., Dijols, S., Dansette, P. M., Mansuy, D., and Stout, C. D. (2003) Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 Å resolution. Evidence for an induced fit model of substrate binding. Biochemistry 42, 9335-9345
22. Schoch, G. A., Yano, J. K., Wester, M. R., Griffin, K. J., Stout, C. D., and Johnson, E. F. (2004) Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid-binding site. J. Biol. Chem. 279, 9497-9503 (Pubitemid 38296017)
23. Scott, E. E., He, Y. A., Wester, M. R., White, M. A., Chin, C. C., Halpert, J. R., Johnson, E. F., and Stout, C. D. (2003) An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution. Proc. Natl. Acad. Sci. U.S.A. 100, 13196-13201 (Pubitemid 37444718)
24. Yano, J. K., Hsu, M. H., Griffin, K. J., Stout, C. D., and Johnson, E. F. (2005) Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat. Struct. Mol. Biol. 12, 822-823 (Pubitemid 43086258)
25. Crespi, C. L., Steimel, D. T., Penman, B. W., Korzekwa, K. R., Fernandez-Salguero, P., Buters, J. T., Gelboin, H. V., Gonzalez, F. J., Idle, J. R., and Daly, A. K. (1995) Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. Pharmacogenetics 5, 234-243
26. Ellis, S. W., Rowland, K., Ackland, M. J., Rekka, E., Simula, A. P., Lennard, M. S., Wolf, C. R., and Tucker, G. T. (1996) Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol. Biochem. J. 316, 647-654 (Pubitemid 26182166)
27. von Bahr, C., Spina, E., Birgersson, C., Ericsson, O., Göransson, M., Henthorn, T., and Sjöqvist, F. (1985) Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem. Pharmacol. 34, 2501-2505 (Pubitemid 15063085)
28. Shin, J. G., Soukhova, N., and Flockhart, D. A. (1999) Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro. Preferential inhibition of CYP2D6. Drug Metab. Dispos. 27, 1078-1084 (Pubitemid 29409646)
29. Hanna, I. H., Kim, M. S., and Guengerich, F. P. (2001) Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation. The role of aspartate 301 in structural integrity. Arch. Biochem. Biophys. 393, 255-261 (Pubitemid 32907182)
30. Berka, K., Hendrychová, T., Anzenbacher, P., and Otyepka, M. (2011) Membrane position of ibuprofen agrees with suggested access path entrance to cytochrome P450 2C9 active site. J. Phys. Chem. A 115, 11248-11255
31. Cojocaru, V., Balali-Mood, K., Sansom, M. S., and Wade, R. C. (2011) Structure and dynamics of the membrane-bound cytochrome P450 2C9. PLoS Comput. Biol. 7, e1002152
32. Kuzmic, P., Hill, C., and Janc, J. W. (2004) Practical robust fit of enzyme inhibition data. Methods Enzymol. 383, 366-381 (Pubitemid 38401797)
33. Kuzmic, P. (2009) DynaFit. A software package for enzymology. Methods Enzymol. 467, 247-280
34. Kleywegt, G. J., and Jones, T. A. (1994) Detection, delineation, measurement, and display of cavities in macromolecular structures. Acta Crystallogr. D Biol. Crystallogr. 50, 178-185 (Pubitemid 2054290)
35. Hande, K. R., Collier, M., Paradiso, L., Stuart-Smith, J., Dixon, M., Clendeninn, N., Yeun, G., Alberti, D., Binger, K., and Wilding, G. (2004) Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clin. Cancer Res. 10, 909-915 (Pubitemid 38198889)
36. Pearson, J., Dahal, U. P., Rock, D., Peng, C. C., Schenk, J. O., Joswig-Jones, C., and Jones, J. P. (2011) The kinetic mechanism for cytochrome P450 metabolism of type II binding compounds. Evidence supporting direct reduction. Arch. Biochem. Biophys. 511, 69-79
37. Masuda, K., Tamagake, K., Okuda, Y., Torigoe, F., Tsuzuki, D., Isobe, T., Hichiya, H., Hanioka, N., Yamamoto, S., and Narimatsu, S. (2005) Change in enantioselectivity in bufuralol 1-hydroxylation by the substitution of phenylalanine-120 by alanine in cytochrome P450 2D6. Chirality 17, 37-43 (Pubitemid 39665573)